Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2615-2619

  Santoro, A ^a   Bredenfeld, H ^a   Devizzi, L ^a   Tesch, H ^a   Bonfante, V ^a   Viviani, S ^a   Fiedler, F ^a   Soto Parra, H ^a   Benoehr, C ^a   Pacini, M ^a   Bonadonna, G ^a   Diehl, V ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; ALLERGIC REACTION; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SURVIVAL TIME;

EID: 0033932803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2615     Document Type: Article

References (43)

1. Santoro A, Bonfante V. Viviani S. et al: Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 15:415a, 1996 (abstr 1271)
2. Hoppe RT, Cosset JM, Santoro A, et al: Treatment of unfavorable prognosis, stage I-II Hodgkin's disease, in Mauch PM, Armitage JO, Diehl V, et al (eds): Hodgkin's Disease. Baltimore. MD, Lippincott Williams & Wilkins, 1999, chap 26
3. Rosenberg SA: Modern combined modality management of Hodgkin's disease. Curr Opin Oncol 6:470-472, 1994
4. Longo DL, Young RC, Wesley M. et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
5. Santoro A, Bonadonna G. Bonfante V, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
6. Santoro A, Bonadonna G, Bonfante V, et al: Alternating drug combination in the treatment of advanced Hodgkin's disease. N Engl J Med 306:770-775, 1992
7. Bonadonna G. Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Intern Med 104:739-746, 1986
8. Canellos JP, Anderson J, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP. ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
9. Aisenberg AC: Problems in Hodgkin's disease management. Blood 93:761-779, 1999
10. Diehl V, Franklin J, Hasenclever D, et al: BEACOPP: A new dose-escalated and accelerated regimen is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma - Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-3821, 1998
11. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 7:105-108, 1996
12. Viviani S, Bonfante V. Santoro A, et al: Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 5:275-282, 1999
13. Santoro A, Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol 2:101-105, 1979
14. Horning SJ: Primary refractory Hodgkin's disease. Ann Oncol 9:97-101, 1998
15. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534, 1997
16. Canellos GP: Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors. Ann Oncol 9:91-96, 1998
17. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992
18. Viviani S, Santoro A, Negretti E, et al: Salvage chemotherapy in Hodgkin's disease: Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1:123-127, 1990
19. Bierman PJ, Anderson JR, Freeman MB, et al: High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 7:151-156, 1996
20. Reece DE, Barnett MJ, Shepherd JD, et al: High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456, 1995
21. Forrest DL, Nevill TJ, Connors JM, et al: Long-term follow-up of 100 patients undergoing high-dose chemotherapy (HDCT) and autologous stem-cell transplatation (ASCT) for Hodgkin's disease (HD). Proc Am Soc Hematol 90:593a, 1997 (abstr 2636)
22. Gianni AM, Siena S, Bregni M, et al: High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: A six-year update. Ann Oncol 4:889-891, 1993
23. Chopra R, McMillan AK, Linen DC, et al: The place of high-dose BEAM therapy and autologous bone marrow transplatation in poor-risk Hodgkin's disease: A single-centre eight-years study of 155 patients. Blood 81:1137-1145, 1993
24. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for current or refractory Hodgkin's disease. Blood 89:814-822, 1997
25. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanism of action. Semin Oncol 23:3-15, 1996
26. Bouffard DY, Momparler LF, Momparler RL: Comparison of antineoplastic activity of 2′, 2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs 2:49-55, 1991
27. Csoka K, Liliemark J, Larsson R. et al: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol, 22:47-53, 1995
28. Bouffard DY, Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 19:849-856, 1995
29. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review. Cancer 78:633-638, 1996
30. Steward WP: Combination studies with gemcitabine in the treatment of non-small cell lung cancer. Br J Cancer 78:15-19, 1998 (suppl 3)
31. Stadler WM, Kuzel TM, Raghavan D, et al: Metastatic bladder cancer: Advances in treatment. Eur J Cancer 33:23-26, 1997 (suppl 1)
32. Friedlander M, Millward MJ, Bell D, et al: A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9:1343-1345, 1998
33. Luftner D, Flath B, Akrivakis C, et al: Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124:527-531, 1998
34. Hitt R, Castellano D, Hidalgo M, et al: Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol 9:1347-1349, 1998
35. Zinzani PL, Magagnoli M, Bendandi M, et al: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351-1353, 1998
36. Bernell P, Ohm L: Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol 101:203-204, 1998
37. Fossa A, Santoro A, Hiddemann W, et al: Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 17:3786-3792, 1999
38. Thomas A, Steward WP: Gemcitabine: A major advance? Ann Oncol 9:1265-1267, 1998
39. Green MR: Gemcitabine safety overview. Semin Oncol 23:32-35, 1996
40. Borchmann P, Schnell R, Diehl V, et al: New drugs in the treatment of Hodgkin's disease. Ann Oncol 9:103-108, 1998
41. Devizzi L, Santoro A, Bonfante V, et al: Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5:817-820, 1994
42. Ferme C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 6:517-518, 1995
43. Bonfante V. Viviani S, Santoro A, et al: Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 77:992-997, 1998